Ann: Voluntary Suspension, page-443

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 443 Last

Share
Profile

Follow
$tockfella

3,150 Posts.

1293

09/08/17

08:50

Post #: 26378130
Share

Originally posted by mariolordz ↑

Whether you're on the positive or negative side of this debate, the following is very clear:

1. The idea is compelling, has many applications and overall great potential.

2. At present, the company has no earnings. It's present valuation at 200 million is purely speculative.

3. Initial holders have long since sold out of the business.

4. The voluntary suspension to delay a week, followed a TH which in itself represented a delay of over a month on the expectation clearly set by management for delivery of results.

Two things are clear...

1. Given the speculative valuation, and management's language around these results, they are absolutely critical to the SP, which means...

2. IF trading resumes (i.e. they don't extend the VS), no matter what the result, we'll see a big SP shift.

Personally, the fact that many initial holders have sold out of the business, prior to what was purported to be the biggest windfall (results/FDA) was cause enough for caution (hence my holding is relatively small). However, following management's consistent failure to meet expectations on delivery dates and with a zero cash flow valuation of 200 million, I'm less certain that even my small exposure is worth the risk.

Time will tell...

Expand

Who are you? Never seen your name here before. First post ever and you take the time to write all this. Yeah, ok. Seems legit to me.

RAP Price at posting: 31.0¢ Sentiment: Buy Disclosure: Held
18 Upvote

0 Great analysis

Reply

Top Stories

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

Good habits matters when it comes to finances

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN